- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Government Recovers $200 Million From State Health Exchanges
What we're reading, December 9, 2015: the federal government recovered $200 million from state's whose health insurance exchanges faltered; drug cocktails are responsible for majority of drug overdose deaths in Massachusetts; and healthcare organizations are not confident in their ability to share patient data while protecting patient privacy.
The Affordable Care Act remains a controversial topic in the United States, but the government recently announced it has been able to recoup more than $200 million in funding from states that tried to set up their own health insurance exchanges and ran into problems. The federal government had granted more than $4 billion to 17 states, but exchanges have struggled and Hawaii, Nevada, and Oregon all chose to close their exchanges, reported The Wall Street Journal.
The majority of drug overdose deaths in Massachusetts are being attributed to drug cocktails that combine a prescription opioid or heroin with some other drug or alcohol. Kaiser Health News reported that an analysis from the Harvard T.H. Chan School of Public Health found fentanyl, which is more powerful than heroin, was present in more than one-third of the deaths. Even physicians specializing in addiction medicine and who treat patients in recovery face the challenge of what to prescribe that won’t cause a serious adverse reaction.
Demand for access to health data is on the rise, but healthcare organizations might not be able to ensure patient privacy, according to a new survey. More than two-thirds of healthcare organizations lack complete confidence in their ability to share data without risking patients’ privacy, according to Healthcare Informatics. In addition, the survey found individuals lack familiarity with advanced methods of de-identifying data and most organizations use data sharing approaches that increase risk.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
